The world-renowned diabetes researcher who announced his move last month from the University of Pittsburgh School of Medicine to the Allegheny Health Network has not taken all 19 Pitt researchers with him, as originally announced. AHN said last month Massimo Trucco, the pediatric immunologist formerly based at Children’s Hospital of UPMC of Pittsburgh and working to cure Type 1 diabetes, would move to AHN to lead its newly created Institute for Cellular Therapeutics. Alejandro Soto-Gutierrez, a Pitt assistant professor of pathology, and his research team of four transplant surgeons, a biologist and a pathologist, decided against the move. “We did not feel that it was a good fit for our research.” His focus is development of entire replacement organs. Dr. Trucco is preparing to begin Phase
Endocrinology | A combination of sitagliptin and lansoprazole did not halt the destruction of beta-cell function in patients recently-diagnosed with type 1 diabetes, according to research published in The Lancet Diabetes & Endocrinology. “One half of the group taking active sitagliptin and lansoprazole failed to increase the hormones on which our hypothesis was based: glucagon-like peptide-1 and
A collaborative group from Boston University and Massachusetts General Hospital is working together to make automated blood glucose control a reality, and they have announced their results from the Bionic Pancreas study. Scott, who is also a 20 year+ Type 1 Diabetic on an insulin pump, sits down with Dr. Steven Jon Russell, MD, PhD to talk about this project and it's ramifications.